{"schema_version":"secwatch.filing_event.v1","accession":"0001867096-25-000156","form_type":"8-K","ticker":"XERS","cik":"0001867096","company_name":"Xeris Biopharma Holdings, Inc.","filed_at":"2025-11-06T23:59:59+00:00","discovered_at":"2026-05-14T18:02:40.884808+00:00","generated_at":"2026-05-17T00:00:59.119277+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Xeris Q3 product revenue $74M (+40% YoY); raises FY2025 guidance to $285-290M","bullets":["Total product revenue $74.1M, up 40% YoY; total revenue $74.4M (+37% YoY).","Recorlev revenue $37.0M (+109% YoY); Gvoke $25.2M (+10%); Keveyis $11.9M (-2%).","Net income $0.6M vs net loss $15.7M in Q3 2024; adjusted EBITDA $17.4M.","FY2025 total revenue guidance raised to $285-290M from $280-290M, implying ~42% growth at midpoint.","CEO cites record quarter driven by increased patient demand across all three products."],"urls":{"canonical":"https://secwatch.observer/filing/0001867096-25-000156","json":"https://secwatch.observer/filing/0001867096-25-000156.json","markdown":"https://secwatch.observer/filing/0001867096-25-000156.md","text":"https://secwatch.observer/filing/0001867096-25-000156.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1867096/000186709625000156/0001867096-25-000156-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1867096/000186709625000156/xers-20251106.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T00:00:59.119277+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}